ReviewFrontiers in pediatrics2025
The evolving landscape of pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Closing the policy gap: including children in the global agenda for steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Article
- Gut Microbiome Responses to Nutritional and Lifestyle Interventions in Pediatric Obesity: A Systematic Review Toward Precision Nutrition.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise in pediatric obesity has paralleled an alarming increase in metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). MASLD in children represents a significant public health concern due to its potential progression to advanced liver disease and its association with a myriad of cardiometabolic comorbidities. This review elucidates the risk and consequences of pediatric MASLD in the population of children with obesity. It also identifies critical research gaps and outlines future directions for the prevention, diagnosis, and treatment of pediatric MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.